Iovance Biotherapeutics stock finished the session up 2.1% at US$6.34, a measured move for a company that just posted its strongest quarter yet. The market’s first read seems cautious rather than euphoric, even with record Q2 revenue of US$99.3m and an all time high gross margin near 56% in a high spend biotech model.

The real tension for you as an investor is simple: the share price is reacting to a single day of sentiment, while the earnings print points to improving loss per share and a balance sheet that management believes can fund operations into the second half of 2028.

Is Iovance Biotherapeutics stock a genuine bargain at 8.8x P/S and a DCF value far above US$6.34, or is the market flagging real risk instead? Compare the…